Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

5NIF

Yeast 20S proteasome in complex with Blm-pep activator

Replaces:  4ZZG
Summary for 5NIF
Entry DOI10.2210/pdb5nif/pdb
DescriptorProteasome subunit alpha type-1, Proteasome subunit beta type-3, Proteasome subunit beta type-4, ... (20 entities in total)
Functional Keywords20s proteasome, low-molecular mass activators, allosteric regulation, hydrolase
Biological sourceSaccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)
More
Cellular locationCytoplasm : P21243 P25451 P22141 P30656 P23724 P30657 P23639 P23638 P40303 P32379 P40302 P21242 P38624 P25043
Total number of polymer chains30
Total formula weight772611.80
Authors
Witkowska, J.,Grudnik, P.,Golik, P.,Dubin, G.,Jankowska, E. (deposition date: 2017-03-23, release date: 2017-08-02, Last modification date: 2024-01-17)
Primary citationWitkowska, J.,Gizynska, M.,Grudnik, P.,Golik, P.,Karpowicz, P.,Giedon, A.,Dubin, G.,Jankowska, E.
Crystal structure of a low molecular weight activator Blm-pep with yeast 20S proteasome - insights into the enzyme activation mechanism.
Sci Rep, 7:6177-6177, 2017
Cited by
PubMed Abstract: Proteasomes are responsible for protein turnover in eukaryotic cells, degrading short-lived species but also removing improperly folded or oxidatively damaged ones. Dysfunction of a proteasome results in gradual accumulation of misfolded/damaged proteins, leading to their aggregation. It has been postulated that proteasome activators may facilitate removal of such aggregation-prone proteins and thus prevent development of neurodegenerative disorders. However, the discovery of pharmacologically relevant compounds is hindered by insufficient structural understanding of the activation process. In this study we provide a model peptidic activator of human proteasome and analyze the structure-activity relationship within this novel scaffold. The binding mode of the activator at the relevant pocket within the proteasome has been determined by X-ray crystallography. This crystal structure provides an important basis for rational design of pharmacological compounds. Moreover, by providing a novel insight into the proteasome gating mechanism, our results allow the commonly accepted model of proteasome regulation to be revisited.
PubMed: 28733623
DOI: 10.1038/s41598-017-05997-4
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3 Å)
Structure validation

231029

數據於2025-02-05公開中

PDB statisticsPDBj update infoContact PDBjnumon